Video

Q&A With Ayman Tourbah From University Hospital of Reims: Treatment For Progressive Multiple Sclerosis Still Lags Behind Relapsing Form

Author(s):

In the world of multiple sclerosis treatment the relapsing remitting form of the disease is well ahead of the primary progressive form.

In the world of multiple sclerosis treatment the relapsing remitting form of the disease is well ahead of the primary progressive form. That is starting to change as more therapies and medications work their way through the regulatory approval process.

Professor Ayman Tourbah from the University Hospital of Reims in France discussed what can be done to help level the playing field in the treatment of this form of the disease during the ECTRIMS conference in Barcelona.

While there are considerably more treatment options available for relapsing multiple sclerosis there is considerable research being conducted to help patients with primary progressive multiple sclerosis.

Related Videos
Yehuda Handelsman, MD: Insulin Resistance in Cardiometabolic Disease and DCRM 2.0 | Image Credit: TMIOA
Nathan D. Wong, MD, PhD: Growing Role of Lp(a) in Cardiovascular Risk Assessment | Image Credit: UC Irvine
Laurence Sperling, MD: Expanding Cardiologists' Role in Obesity Management  | Image Credit: Emory University
Laurence Sperling, MD: Multidisciplinary Strategies to Combat Obesity Epidemic | Image Credit: Emory University
Schafer Boeder, MD: Role of SGLT2 Inhibitors and GLP-1s in Type 1 Diabetes | Image Credit: UC San Diego
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Alice Cheng, MD: Exploring the Link Between Diabetes and Dementia | Image Credit: LinkedIn
Orly Vardeny, PharmD: Finerenone for Heart Failure with EF >40% in FINEARTS-HF | Image Credit: JACC Journals
Matthew J. Budoff, MD: Impact of Obesity on Cardiometabolic Health in T1D | Image Credit: The Lundquist Institute
© 2024 MJH Life Sciences

All rights reserved.